Newscast – Page 3 – media

R&D investment in the first half of the year is about 750 billion yuan listed companies become the main force of science and technology innovation

For some time now, the A-share market has been under continuous pressure due to complex internal and external market factors, making it difficult to give full play to resource allocation, value discovery, wealth management and investment functions. No matter how the market evolves and develops, it always has its own laws. Seeing history clearly will help us discover the future. At present, broaden the horizons, calm thinking, help to accurately grasp the historical orientation of the A-share market, see the stock market supply and demand relationship of the marginal improvement, waiting for the active market series of initiatives to accumulate thick into the momentum, landing effect. Recently, the Securities Times launched a series of reports, “Discover the value of A-share investment”, through in-depth interviews and data mining, multi-angle presentation of the A-share market is undergoing positive changes, in order to cohesion of consensus, boost confidence, and jointly promote the A-share ...
- Source: https://finance.eastmoney.com/a/202409123181302392.html
- 103
- September 12, 2024
Ten measures are favorable for innovative medical devices

Recently, the Guangzhou Municipal Health Commission of Guangdong Province issued the “Ten Measures of the Guangzhou Municipal Health Commission to Support the High-quality Development of Innovative Drugs and Devices”, covering the entire process of product research and development-hospital use-payment expansion. The notice proposes to urge medical institutions to hold at least one working meeting of the medical device-related committee every quarter, and hold a meeting within one month after the publication of the “Guangzhou Innovative Drug and Device Product Catalog”, and promptly include innovative drugs and devices in the medical institution’s drug or device catalog as needed, so as to achieve “all-out allocation” and give priority to selection. Encourage qualified medical institutions to accelerate the application of innovative medical devices such as active surgical instruments, passive implantable devices, medical software, medical imaging, radiotherapy, surgical robots, etc., and orderly promote the iterative upgrade of medical institutions’ equipment and facilities. ...
- Source: https://mp.weixin.qq.com/
- 57
- September 12, 2024
The highest increase was 103398%! The revenue of these pharmaceutical companies soared

In September, the 2024 semi-annual reports of various companies have basically been disclosed. According to statistics from Cyber Blue, among the 493 A-share listed pharmaceutical companies (according to the industry classification of Tonghuashun, the same below), the number of companies with year-on-year decline and growth is close to “50-50” – 242 pharmaceutical companies have a year-on-year decline in revenue, accounting for 49% of the total; 252 have an increase in revenue, accounting for 51% of the total. Among the 242 pharmaceutical companies whose revenue decreased compared with the same period last year, 40% of them fell by less than 10%; there were 12 companies with a decline of more than 50%, of which the company with the largest decline had a year-on-year revenue decline of more than 97%. Among the 252 pharmaceutical companies with year-on-year revenue growth, 183 had an increase of less than 20%, accounting for ...
- Source: https://mp.weixin.qq.com/
- 72
- September 12, 2024
The first domestic new drug for alopecia areata is about to be launched

Recently, Hengrui Medicine announced that its application for marketing authorization of emasitinib sulfate tablets (SHR0302 tablets) was accepted by the National Medical Products Administration for the treatment of severe alopecia areata in adults. It is the first domestic JAK inhibitor to be accepted for marketing approval for alopecia areata indications in China. This also means that after Eli Lilly and Pfizer products have been approved in China, Hengrui is likely to become the first domestic company to enter the domestic alopecia areata market. Severe alopecia areata in adults is the fourth indication reported by emasitinib. Last year, it also reported moderate to severe atopic dermatitis, ankylosing spondylitis, and moderate to severe active rheumatoid arthritis in adults and adolescents aged 12 and above. Referring to the progress of Pfizer’s application for listing of Litixitinib Capsules accepted by the National Medical Products Administration in September 2022, included in the ...
- Source: https://mp.weixin.qq.com/
- 89
- September 11, 2024
cochlear implants and other high-value medical supplies will be included in the scope of collection and procurement

September 10, 2011 – The State Council Information Office held a series of press conferences on the theme of “promoting high-quality development” on the morning of the 10th, Yan Qinghui, deputy director of the State Medical Insurance Bureau, said at the meeting that the medical insurance sector will vigorously promote the expansion of the quality of the collection of medicine and mining. Continuously expand the coverage of collection, carry out a new batch of national organization drugs and high-value medical supplies collection, will be cochlear implants and other high-value medical supplies into the collection. Yan Qinghui introduced, the effectiveness of the collection work can be recognized from three aspects: First, the burden of drug use by the public has been reduced, and the accessibility and quality of drugs have been improved. For example, hepatitis B antiviral drugs entecavir and tenofovir, etc., the annual cost of patients before the ...
- Source: https://finance.eastmoney.com/a/202409103179908838.html
- 109
- September 11, 2024
FDA Approves Luye Pharma Group’s Erzofri for Adults with Schizophrenia, Schizoaffective Disorder

By Don Tracy, Associate Editor Erzofri is the first patented paliperidone palmitate long-acting injectable developed in China to receive FDA approval for treating schizophrenia and schizoaffective disorder, company says. Image Credit: Adobe Stock Images/Mohammad Xte The FDA has approved Luye Pharma Group’s Erzofri (paliperidone palmitate) extended-release injectable suspension for treating schizophrenia and schizoaffective disorder in adults. According to the company, the treatment is the first patented paliperidone palmitate long-acting injection developed in China to be approved in the United States. The product was granted a US patent in 2023, set to expire in 2039, and was approved as a new drug under the 505(b)(2) pathway.1 The approval is based on results from the company’s pivotal United States study of Erzofri.1 “The purpose of developing innovative formulations is to address unmet clinical needs, which includes covering aspects such as drug efficacy, compliance issues and side effects, among others. With a focus on ...
- Source: drugdu
- 121
- August 1, 2024
With FDA Nod for Colorectal Cancer Screening, How Much Market Share Can Guardant’s Blood Test Get?

Guardant Health’s Shield, a liquid biopsy that screens for colorectal cancer by analyzing a patient blood sample, will compete against stool-based tests already established in the market. Shield could also face new competition from other liquid biopsy companies. By Frank Vinluan FDA approval of a Guardant Health blood test that screens for colorectal cancer makes it the first liquid biopsy approved for this type of cancer, clearing the way to make this test more accessible to more people. But commercialization will be a challenge as the new test is not expected to become the first or even second screening option for patients. The approval announced Monday for the test, named Shield, covers the screening of adults age 45 and older at average risk for colorectal cancer. Colorectal cancer is the third most common type of cancer in the U.S., excluding skin cancers, according to the American Cancer Society. For men and women combined, it’s ...
- Source: drugdu
- 122
- August 1, 2024
Blood Test Predicts Alzheimer’s Disease with Over 90% Accuracy

Alzheimer’s disease impacts one in five women and one in ten men over their lifetimes, yet diagnostic tools are still often cumbersome and not widely accessible in primary care settings. Although specialized memory clinics frequently use advanced diagnostic methods like PET scans and cerebrospinal fluid tests, there is a significant need for simpler, quicker diagnostic tools that can be used in primary care. Now, a commercially available blood test for Alzheimer’s has demonstrated approximately 90% reliability in primary care settings, representing a major development for individuals seeking assistance for memory loss and suspected of having this neurological disease. Research on this innovative blood testing method, which evaluates levels of Plasma Phospho-Tau217, commenced in 2019 with studies showing that the blood test can detect Alzheimer ‘s-related changes even before symptoms appear and monitor the disease’s progression. Earlier this year, results indicated that this blood test is as reliable as, and ...
- Source: drugdu
- 133
- August 1, 2024
Groundbreaking Microarray Immunoassay Simultaneously Detect 30+ Allergens from Single Blood Sample

A revolutionary microarray immunoassay enables patients to receive results for multiple allergens using just a single blood sample, thereby minimizing the necessity for multiple tests and appointments. AliveDx’s (Eysins, Switzerland) groundbreaking microarray immunoassay is specifically designed to detect specific IgE antibodies directed against protein allergens in human serum and runs on the company’s proprietary MosaiQ platform. This multiplex immunoassay microarray is capable of detecting over 30 allergens, including those from both inhalants and foods and represents a significant leap in diagnostic capabilities by allowing simultaneous testing for various conditions. This method streamlines the diagnostic process, simplifies laboratory workflows, and reduces the manual labor typically associated with singleplex testing methods. Consequently, it saves significant time for both laboratories and clinicians, enhancing the ability to efficiently diagnose and exclude multiple conditions. For patients who are sensitized to multiple allergens, this technology offers a rapid, comprehensive diagnostic process and supports more targeted ...
- Source: drugdu
- 113
- August 1, 2024
MIT study reveals how specific cells in AD become vulnerable and resilient

The neurodegenerative condition is recognised as the most common form of dementia A study conducted by researchers at the Massachusetts Institute of Technology (MIT) has revealed how specific cells and circuits become vulnerable and resilient to cognitive decline in Alzheimer’s disease (AD), despite clear signs of disease pathology. Published in Nature, researchers measured gene expression differences using single-cell RNA profiling in more than 1.3 million cells of over 70 different cell types in six brain regions, including the prefrontal cortex, entorhinal cortex and hippocampus, from 48 tissues donated by the Religious Order Study and the Rush Memory and Aging Project at Rush University, 26 of whom had died with an AD diagnosis and 22 of whom had not. Currently the most common form of dementia, AD is a neurodegenerative condition that deteriorates the brain’s memory and thinking skills. Researchers found that one type of excitatory neuron in the hippocampus and four ...
- Source: https://ramaonhealthcare.com/mit-study-reveals-how-specific-cells-in-ad-become-vulnerable-and-resilient/
- 122
- August 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.